Literature DB >> 19393108

Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist.

Catherine A O'Malley1.   

Abstract

Cystic fibrosis (CF) is a complex genetic disease characterized by lung infections that lead to early morbidity and death. Pathogens that commonly infect the lungs of patients with CF include Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia. Aggressively treating pulmonary infection with antibiotics has contributed to improved survival in patients with CF but has also promoted multiple-drug-resistant bacteria. Other complexities include the ability of bacteria to form biofilms, which makes them more resistant to antibiotics, and emerging pathogens in CF, of which the clinical importance is not yet clear. Increasing evidence of patient-to-patient transmission of CF pathogens led the Cystic Fibrosis Foundation to produce evidence-based infection-control recommendations, which stress 4 principles: standard precautions, transmission-based precautions, hand hygiene, and care of respiratory equipment. Respiratory therapists need to know and follow these infection-control recommendations. Cohorting patients infected with B. cepacia complex is one of several interventions successful at keeping the spread of this pathogen low, but cohorting patients who are infected/colonized with other microbes is controversial, the main argument of which is not being certain of a patient's present respiratory culture status at any given patient visit.

Entities:  

Mesh:

Year:  2009        PMID: 19393108     DOI: 10.4187/aarc0446

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  18 in total

Review 1.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.

Authors:  Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

3.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

4.  Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis.

Authors:  Basant A Abdulrahman; Arwa Abu Khweek; Anwari Akhter; Kyle Caution; Sheetal Kotrange; Dalia H A Abdelaziz; Christie Newland; Roberto Rosales-Reyes; Benjamin Kopp; Karen McCoy; Richard Montione; Larry S Schlesinger; Mikhail A Gavrilin; Mark D Wewers; Miguel A Valvano; Amal O Amer
Journal:  Autophagy       Date:  2011-11-01       Impact factor: 16.016

Review 5.  Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.

Authors:  David van Duin; David L Paterson
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

6.  A short-term evaluation of a prototype disposable Oscillating Positive Expiratory Pressure (OPEP) device in a cohort of children with cystic fibrosis.

Authors:  Kevin J O'Sullivan; Valerie Power; Barry Linnane; Deirdre McGrath; Magdalena Mulligan; Rebecca White; Leonard W O'Sullivan; Colum P Dunne
Journal:  BMC Pulm Med       Date:  2021-05-12       Impact factor: 3.317

7.  Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles.

Authors:  Ashley J R Carter; Andrew Q Nguyen
Journal:  BMC Med Genet       Date:  2011-12-12       Impact factor: 2.103

8.  Clinical Presentations of Cystic Fibrosis in Iranian Children.

Authors:  Farzaneh Motamed; Mina Moayednia; Nasrin Moayednia; Mehri Najafi Sani; Fatemeh Farahmand; Ahmad Khodadad; Gholamhossein Fallahi
Journal:  Iran J Pediatr       Date:  2015-04-18       Impact factor: 0.364

Review 9.  Multidrug-Resistant Bacteria in the Community: An Update.

Authors:  David van Duin; David L Paterson
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 10.  Antagonistic Pleiotropy in Human Disease.

Authors:  Sean G Byars; Konstantinos Voskarides
Journal:  J Mol Evol       Date:  2019-12-21       Impact factor: 3.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.